- Not enactedThe President has not signed this bill
- The senate has not voted
- The house has not voted
Committee on Energy and CommerceCommittee on Ways and MeansIntroducedJune 11th, 2013
- house Committees
Bill DetailsOfficial information provided by the Congressional Research Service. Learn more or make a suggestion.
The Congressional Research Service writes summaries for most legislation. These summaries are listed here. Countable will update some legislation with a revised summary, title or other key elements.
Preserving Access to Orphan Drugs Act of 2013
To clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers.
Preserving Access to Orphan Drugs Act of 2013 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions (orphan drug) from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million. Makes this Act effective as if included in PPACA.